Li Yu, Zhao Yuanyuan, Li Xiaona, Zhai Liuqun, Zheng Hua, Yan Ying, Fu Qiang, Ma Jinlian, Fu Haier, Zhang Zhenqiang, Li Zhonghua
Department of Pharmacy, Yellow River Central Hospital of Yellow River Conservancy Commission, Zhengzhou, China.
Department of Pharmacy, The Third Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Front Pharmacol. 2022 Oct 25;13:1020556. doi: 10.3389/fphar.2022.1020556. eCollection 2022.
Alzheimer's disease (AD) is a common chronic neurodegenerative disease characterized by cognitive learning and memory impairments, however, current treatments only provide symptomatic relief. Lysine-specific demethylase 1 (LSD1), regulating the homeostasis of histone methylation, plays an important role in the pathogenesis of many neurodegenerative disorders. LSD1 functions in regulating gene expression transcriptional repression or activation, and is involved in initiation and progression of AD. Pharmacological inhibition of LSD1 has shown promising therapeutic benefits for AD treatment. In this review, we attempt to elaborate on the role of LSD1 in some aspects of AD including neuroinflammation, autophagy, neurotransmitters, ferroptosis, tau protein, as well as LSD1 inhibitors under clinical assessments for AD treatment.
阿尔茨海默病（AD）是一种常见的慢性神经退行性疾病，其特征为认知、学习和记忆障碍，然而，目前的治疗方法仅能缓解症状。赖氨酸特异性去甲基化酶1（LSD1）调节组蛋白甲基化的稳态，在许多神经退行性疾病的发病机制中起重要作用。LSD1在调节基因表达（转录抑制或激活）中发挥作用，并参与AD的发生和发展。对LSD1的药理学抑制已显示出对AD治疗有潜在的治疗益处。在本综述中，我们试图阐述LSD1在AD的某些方面所起的作用，包括神经炎症、自噬、神经递质、铁死亡、tau蛋白，以及正在进行AD治疗临床评估的LSD1抑制剂。
